Caricamento...

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape

Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 14% of all lung cancer diagnoses. Despite decades of active research, treatment options for SCLC are limited and resistance to the few Food and Drug Administration (FDA) approved therapies develops rapidly. With no approved...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Lung Cancer Res
Autori principali: Sen, Triparna, Gay, Carl M., Byers, Lauren Averett
Natura: Artigo
Lingua:Inglês
Pubblicazione: AME Publishing Company 2018
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5835589/
https://ncbi.nlm.nih.gov/pubmed/29535912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2018.02.03
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !